Immunomic Therapeutics to Present at the 2018 World Vaccine & Immunotherapy Congress

SAN DIEGO--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy Congress West Coast, being held November 28-29 in San Diego, CA.

Dr. Teri Heiland, Senior Vice President of R&D, and Sia Anagnostou, Senior Director of Corporate Development, will discuss ITI’s investigational UNiversal Intracellular Targeted Expression (UNITE) technology platform, designed to utilize the body’s natural biochemistry to generate broad immune responses, during a presentation and panel discussion. ITI’s UNITE platform has potentially broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. ITI has built a large pipeline from UNITE with seven oncology programs, with its lead program in Phase II for GBM, and an allergy program which is fully licensed to ITI’s partner, Astellas Pharma, Inc.

Details of ITI’s presentation and panel participation are listed below:

Presentation: “Immunomic is Addressing the Challenges of Viral Targets in Cancer”

When: Wednesday, November 28, at 12:50 p.m. PST
Who: Teri Heiland, Ph.D., Co-Founder and Senior Vice President of Research and Development at Immunomic Therapeutics, Inc.
Where: Loews Coronado Bay Resort, 4000 Coronado Bay Road, Coronado, CA 92118

Panel: “Immunotherapy in Cancer – Combinations Are Key”

When: Thursday, November 29, at 9:10 a.m. PST
Who: Moderated by Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc.
Participants include:

• Teri Heiland, Ph.D., Co-Founder and Senior Vice President of Research and Development at Immunomic Therapeutics
• Sylvaine Cases, Ph.D., Vice President of Oncology Scientific Innovation at Janssen Research & Development
• Peter Emtage, Ph.D., Senior Vice President and Global Head of Cell Therapy Research at Kite, a Gilead Company
• Amy Conrad, Founder and CEO of Juniper Point
• Raghuram Selvaraju, Ph.D., MBA, Managing Director & Head of Equity Research, H.C. Wainwright & Co.

Where: Loews Coronado Bay Resort, 4000 Coronado Bay Road, Coronado, CA 92118

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to generate broad immune responses. ITI’s UNITE platform has potentially broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI's technology has been deployed in over 135 oncology patients and 210 allergy patients and in oncology, has demonstrated survival benefit and immune system activation in the clinic. Due to its expertise in the field, ITI entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005029/en/